3 years survival of patients with multiple myeloma.
<strong>Background:</strong> The survival of patients with multiple myeloma varies. Frequently we don’t identify the patients that could be cured with advanced therapies, nor even recognize those, in which we expect a long survival with the classic treatment measures. That’s why it is ne...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | Spanish |
Published: |
Centro Provincial de Información de Ciencias Médicas. Cienfuegos
2006-12-01
|
Series: | Medisur |
Subjects: | |
Online Access: | http://medisur.sld.cu/index.php/medisur/article/view/214 |
id |
doaj-e41ca05b38e449fc96246f91f860585e |
---|---|
record_format |
Article |
spelling |
doaj-e41ca05b38e449fc96246f91f860585e2021-08-27T02:16:44ZspaCentro Provincial de Información de Ciencias Médicas. CienfuegosMedisur1727-897X2006-12-01438132143 years survival of patients with multiple myeloma.Julio Dámaso Fernández ÁguilaAlexander García BlayLuis Alberto Corona MartínezMaritza Cabrera ZamoraLeovaldo Prieto Jiménez.Tamara Guerra Alfonso<strong>Background:</strong> The survival of patients with multiple myeloma varies. Frequently we don’t identify the patients that could be cured with advanced therapies, nor even recognize those, in which we expect a long survival with the classic treatment measures. That’s why it is necessary the study of prognosis factors to achieve an optimum stratification and to individualize the pattern to follow. <strong>Objectives:</strong> To determine the 3 years survival of the patients with multiple mieloma and the factors that influence it. <strong>Methods:</strong> A descriptive study of a series of cases of 50 patients with multiple mieloma. The socio-demographic characteristics were studied, as well as the clinic-humoral state, type of treatment and response to it, the over life curves were calculated by the estimates of Kaplan-Meier. A uni-varied analysis was made for which the patients were stratified in groups, that were compared through the long-rank method. A trust interval of 95% was accepted. <strong>Results:</strong>The total 3 years survival was of 37%. The 58% of the cases used the combination of Melfalan with Prednisona as initial therapeutic scheme. The 47,1% of the treated patients had a positive response to the chemotherapy. There were no alarming differences in response percentage and in survival among those who received Melfalan-prednisona and those who were treated with schemes that combined both drugs. The functional capacity reduction, the association to renal insufficiency, and not having response to treatment were the factors associated to an early mortality. <strong>Conclusions:</strong> The identification by means of this study of the factors related with the illness, would allow us to stratify the sick persons and to individualize its cares to improve the survival.<strong><br /></strong>http://medisur.sld.cu/index.php/medisur/article/view/214mieloma múltiplepronósticofactores de riesgo |
collection |
DOAJ |
language |
Spanish |
format |
Article |
sources |
DOAJ |
author |
Julio Dámaso Fernández Águila Alexander García Blay Luis Alberto Corona Martínez Maritza Cabrera Zamora Leovaldo Prieto Jiménez. Tamara Guerra Alfonso |
spellingShingle |
Julio Dámaso Fernández Águila Alexander García Blay Luis Alberto Corona Martínez Maritza Cabrera Zamora Leovaldo Prieto Jiménez. Tamara Guerra Alfonso 3 years survival of patients with multiple myeloma. Medisur mieloma múltiple pronóstico factores de riesgo |
author_facet |
Julio Dámaso Fernández Águila Alexander García Blay Luis Alberto Corona Martínez Maritza Cabrera Zamora Leovaldo Prieto Jiménez. Tamara Guerra Alfonso |
author_sort |
Julio Dámaso Fernández Águila |
title |
3 years survival of patients with multiple myeloma. |
title_short |
3 years survival of patients with multiple myeloma. |
title_full |
3 years survival of patients with multiple myeloma. |
title_fullStr |
3 years survival of patients with multiple myeloma. |
title_full_unstemmed |
3 years survival of patients with multiple myeloma. |
title_sort |
3 years survival of patients with multiple myeloma. |
publisher |
Centro Provincial de Información de Ciencias Médicas. Cienfuegos |
series |
Medisur |
issn |
1727-897X |
publishDate |
2006-12-01 |
description |
<strong>Background:</strong> The survival of patients with multiple myeloma varies. Frequently we don’t identify the patients that could be cured with advanced therapies, nor even recognize those, in which we expect a long survival with the classic treatment measures. That’s why it is necessary the study of prognosis factors to achieve an optimum stratification and to individualize the pattern to follow. <strong>Objectives:</strong> To determine the 3 years survival of the patients with multiple mieloma and the factors that influence it. <strong>Methods:</strong> A descriptive study of a series of cases of 50 patients with multiple mieloma. The socio-demographic characteristics were studied, as well as the clinic-humoral state, type of treatment and response to it, the over life curves were calculated by the estimates of Kaplan-Meier. A uni-varied analysis was made for which the patients were stratified in groups, that were compared through the long-rank method. A trust interval of 95% was accepted. <strong>Results:</strong>The total 3 years survival was of 37%. The 58% of the cases used the combination of Melfalan with Prednisona as initial therapeutic scheme. The 47,1% of the treated patients had a positive response to the chemotherapy. There were no alarming differences in response percentage and in survival among those who received Melfalan-prednisona and those who were treated with schemes that combined both drugs. The functional capacity reduction, the association to renal insufficiency, and not having response to treatment were the factors associated to an early mortality. <strong>Conclusions:</strong> The identification by means of this study of the factors related with the illness, would allow us to stratify the sick persons and to individualize its cares to improve the survival.<strong><br /></strong> |
topic |
mieloma múltiple pronóstico factores de riesgo |
url |
http://medisur.sld.cu/index.php/medisur/article/view/214 |
work_keys_str_mv |
AT juliodamasofernandezaguila 3yearssurvivalofpatientswithmultiplemyeloma AT alexandergarciablay 3yearssurvivalofpatientswithmultiplemyeloma AT luisalbertocoronamartinez 3yearssurvivalofpatientswithmultiplemyeloma AT maritzacabrerazamora 3yearssurvivalofpatientswithmultiplemyeloma AT leovaldoprietojimenez 3yearssurvivalofpatientswithmultiplemyeloma AT tamaraguerraalfonso 3yearssurvivalofpatientswithmultiplemyeloma |
_version_ |
1721189083417411584 |